MDxHealth Reports Preliminary Q4/FY23 Revenue, Issues 2024 Guidance
Ticker: MDXH · Form: 6-K · Filed: Jan 8, 2024 · CIK: 1872529
| Field | Detail |
|---|---|
| Company | Mdxhealth SA (MDXH) |
| Form Type | 6-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: revenue-guidance, preliminary-results, financial-update
TL;DR
**MDxHealth just dropped preliminary Q4/FY23 revenue and 2024 guidance, so watch for details in the attached press release.**
AI Summary
MDxHealth SA, a medical diagnostics company, filed a 6-K on January 8, 2024, to announce its preliminary fourth quarter and full year 2023 revenues and to provide revenue guidance for 2024. This filing indicates the company is providing an update on its financial performance, which is crucial for investors to assess its current health and future prospects. The press release, attached as Exhibit 99.1, contains the specific financial figures and outlook.
Why It Matters
This filing provides investors with an early look at MDxHealth's financial performance for the recent quarter and year, along with its expectations for the upcoming year, which can influence stock valuation and investment decisions.
Risk Assessment
Risk Level: medium — The risk level is medium because preliminary results can change, and the actual financial figures and guidance are not fully detailed within the 6-K itself but in an attached exhibit.
Analyst Insight
A smart investor would immediately review Exhibit 99.1 to understand the specific preliminary revenue figures for Q4/FY23 and the 2024 guidance, as these details are critical for assessing the company's financial trajectory and making informed investment decisions.
Key Players & Entities
- MDxHealth SA (company) — the registrant filing the 6-K
- Michael McGarrity (person) — Chief Executive Officer who signed the 6-K
- January 8, 2024 (date) — date of the press release and 6-K filing
Forward-Looking Statements
- MDxHealth's stock price will react to the specific revenue figures and guidance provided in Exhibit 99.1. (MDxHealth SA) — high confidence, target: January 9, 2024
- Analysts will update their price targets and ratings for MDxHealth based on the preliminary results and 2024 guidance. (MDxHealth SA) — medium confidence, target: January 2024
FAQ
What is the primary purpose of MDxHealth SA's 6-K filing on January 8, 2024?
The primary purpose of MDxHealth SA's 6-K filing on January 8, 2024, is to furnish a press release (Exhibit 99.1) reporting preliminary fourth quarter and full year 2023 revenues and issuing 2024 revenue guidance.
Who signed the 6-K filing on behalf of MDxHealth SA?
The 6-K filing was signed by Michael McGarrity, the Chief Executive Officer of MDxHealth SA, on January 8, 2024.
Where is MDxHealth SA's principal executive office located?
MDxHealth SA's principal executive office is located at CAP Business Center, Zone Industrielle des Hauts-Sarts, 4040 Herstal, Belgium.
Under which SEC Act is this report filed?
This report is filed under the Securities Exchange Act of 1934, pursuant to Rule 13a-16 or 15d-16.
Is the information in Exhibit 99.1 considered 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934?
No, the information in the attached Exhibit 99.1 is being furnished and shall not be deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.
Filing Stats: 271 words · 1 min read · ~1 pages · Grade level 13.4 · Accepted 2024-01-08 16:39:45
Filing Documents
- ea191338-6k_mdxhealth.htm (6-K) — 11KB
- ea191338ex99-1_mdxhealth.htm (EX-99.1) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-24-001933.txt ( ) — 31KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. MDXHEALTH SA Date: January 8, 2024 By: /s/ Michael McGarrity Name: Michael McGarrity Title: Chief Executive Officer 2